Rigel Pharmaceuticals Inc (RIGL) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $35.71
• Market Cap: $628.40M
• P/E Ratio: 5.57
• EPS: $6.21
• 52-Week High: $52.24
• 52-Week Low: $15.50

Market Sentiment

Rigel Pharmaceuticals Inc currently has a Neutral sentiment score of 0.14.

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. is a biotechnology company based in South San Francisco, California, specializing in the discovery and development of novel small molecule drugs aimed at addressing critical unmet medical needs in blood disorders, cancer, and rare immune diseases. With a strong focus on innovative therapies, Rigel leverages its proprietary drug development platform to advance its pipeline of targeted treatments, aiming to improve patient outcomes in challenging therapeutic areas. T...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Rigel Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does RIGL pay dividends?

Rigel Pharmaceuticals Inc (RIGL) does not currently pay a regular dividend.

What is RIGL's P/E ratio?

Rigel Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 5.57.

What is RIGL's market cap?

Rigel Pharmaceuticals Inc (RIGL) has a market capitalization of $628.40M with a current stock price of $35.71.